05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
Swift Acquisition Corp. v. Krauss, et al., Case No. 2019-0509-PAF (Del. Ch. Aug. 25, 2020)—The Dela...
Read More >
The DE OFCCP Week in Review (WIR) is a simple, fast and direct summary of relevant happenings in the...
Read More >
On Monday, August 17, 2020, Baker Donelson's Clinton Sanko sat down with Wendell Jisa, CEO of Reveal...
Read More >
Tis the season to be jolly, and the National Labor Relations Board (“NLRB” or “Board”) was in an...
Read More >
Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance relat...
Read More >
Raising money is hard. Many founders think that it’ll be easy, and that a dozen investors will be l...
Read More >